Recovery / Discharge

The patients vital signs should be monitored until they are no longer at risk for hypoxaemia. The largest study to date⁵ in which the timing of adverse outcomes can be examined included 353 children receiving ketamine and 672 receiving midazolam and fentanyl. Only 8% of the adverse events occurred after the procedure. In addition, the median time to serious adverse effects was two and a half minutes following the last intravenous medication. No primary adverse event occurred after 25 minutes from the last intravenous medication.

Guidance regarding discharge is given in Table 8.

Table 8: Guidelines for discharge³